SAB ETF

Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year.

NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 24, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 20, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.